During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

An innovative new treatment is set to benefit hundreds of people in England with aggressive blood cancer after it was given ...

A new treatment, lisocabtagene maraleucel, has been approved for NHS use, benefiting hundreds of blood cancer patients in England.